IP Library Granted Patent US 10,046,092
Granted Patent B2
US 10,046,092 · App. 14/731,715 · Granted Aug 14, 2018

Coating formulations for scoring or cutting balloon catheters

Inventors: Ulrich Speck (Berlin, DE); Madeleine Caroline Berg (Berlin, DE)
Assignee: The SPECTRANETICS CORPORATION
A61L29/08A61B17/320725A61L29/143A61L29/16A61L31/16A61M25/10A61M25/104A61B2017/320733A61L2300/216A61L2300/416A61L2300/606A61L2300/802A61M2025/105A61M2025/109
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,046,092
App. No.
14/731,715
Granted
Aug 14, 2018
Kind
B2
Abstract

The present invention is related to scoring or cutting balloon catheters carrying at least on a portion of their surface at least one oxidation-insensitive drug or oxidation-insensitive polymer-free drug preparation and at least one lipophilic antioxidant at a ratio of 3-100% by weight of the at least one lipophilic antioxidant in relation to 100% by weight of the drug, wherein the at least one oxidation-insensitive drug is selected of taxanes, thalidomide, statins, corticoids and lipophilic derivatives of corticoids, and the at least one lipophilic antioxidant is selected of nordihydroguaiaretic acid, resveratrol and propyl gallate.

Claims (26)

1. A balloon catheter for angioplasty or coronary angioplasty comprising:

a shaft having a proximal portion and a distal portion;

an inflatable balloon coupled to the distal portion of the shaft;

a nonimplantable scoring structure surrounding the balloon, wherein the scoring structure is capable of scoring a luminal surface of a blood vessel upon inflation of the inflatable balloon;

wherein the balloon catheter carries on at least on a portion of its surface a therapeutically effective amount of at least one oxidation-insensitive drug and an amount of a lipophilic antioxidant that will protect the drug from premature loss during delivery to the angioplasty site and that is 3-100% by weight of the drug, wherein the at least one oxidation-insensitive drug is selected from the group consisting of: taxanes, thalidomide, statins, corticoids and lipophilic derivatives of corticoids, and the lipophilic antioxidant is nordihydroguaiaretic acid.

2. The balloon catheter according to claim 1 , wherein the scoring structure comprises one or more wires capable of scoring the luminal surface upon inflation of the inflatable balloon.

3. The balloon catheter according to claim 1 , wherein the oxidation-insensitive drug is a taxane selected from the group consisting of paclitaxel, protaxel and docetaxel.

4. The balloon catheter according to claim 3 , wherein the taxane is paclitaxel.

5. The balloon catheter according to claim 1 , wherein the ene antioxidant load is up to 10 μg/mm 2 of coated catheter surface and the antioxidant is provided at a dose level that provides no therapeutic or prophylactic effect.

6. The balloon catheter according to claim 1 , wherein the lipophilic antioxidant is contained at a ratio of 20-100% by weight, in relation to 100% by weight of the at least one oxidation-insensitive drug.

7. The balloon catheter according to claim 1 , wherein the lipophilic antioxidant is contained at a ratio of 50-100% by weight, in relation to 100% by weight of the at least one oxidation-insensitive drug.

8. The balloon catheter according to claim 1 , further comprising a coating composition including the therapeutically effective amount of at least one oxidation-insensitive drug and an amount of lipophilic antioxidant, wherein the coating composition is polymer-free.

9. A balloon catheter for angioplasty or coronary angioplasty comprising:

a shaft having a proximal portion and a distal portion;

an inflatable balloon coupled to the distal portion of the shaft;

a nonimplantable cutting structure surrounding the balloon, wherein the cutting structure is capable of cutting a luminal surface of a blood vessel upon inflation of the inflatable balloon;

wherein the balloon catheter carries on at least on a portion of its surface a therapeutically effective amount of at least one oxidation-insensitive drug and an amount of a lipophilic antioxidant that will protect the drug from premature loss during delivery to the angioplasty site and that is 3-100% by weight of the drug, wherein the at least one oxidation-insensitive drug is selected from the group consisting of: taxanes, thalidomide, statins, corticoids and lipophilic derivatives of corticoids, and the lipophilic antioxidant is nordihydroguaiaretic acid.

10. The balloon catheter according to claim 9 , wherein the at least one drug comprises oxidation-insensitive paclitaxel.

11. A balloon catheter for angioplasty or coronary angioplasty comprising:

a shaft having a proximal portion and a distal portion;

an inflatable balloon coupled to the distal portion of the shaft, wherein the inflatable balloon comprises a surface, wherein at least a portion of the surface carries a therapeutically effective amount of an oxidation-insensitive taxane drug and an amount of nordihydroguaiaretic acid that protects the oxidation-insensitive taxane drug from premature loss during delivery to an angioplasty site, wherein the nordihydroguaiaretic acid is at a ratio of 20-100% by weight, in relation to 100% by weight of the oxidation-insensitive taxane drug; and

a nonimplantable scoring structure surrounding the balloon, wherein the nonimplantable scoring structure is capable of scoring a luminal surface of a blood vessel upon inflation of the inflatable balloon.

12. The balloon catheter according to claim 11 , wherein the scoring structure comprises one or more wires capable of scoring the luminal surface upon inflation of the inflatable balloon.

13. The balloon catheter according to claim 11 , wherein the oxidation-insensitive taxane drug is selected from the group consisting of paclitaxel, protaxel and docetaxel.

14. The balloon catheter according to claim 13 , wherein the taxane is paclitaxel.

15. The balloon catheter according to claim 11 , wherein the nordihydroguaiaretic acid load comprises up to 10 μg/mm 2 of coated catheter surface.

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2024
From: KONINKLIJKE PHILIPS N.V.
To: INNORA HOLDING GMBH
Reel/Frame 066939/0427 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2023
From: ANGIOSCORE LLC
To: SPECTRANETICS LLC
Reel/Frame 062627/0559 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2019
From: SPECK, ULRICH; BERG, MADELEINE CAROLINE
To: ANGIOSCORE, INC.
Reel/Frame 048718/0948 →
RELEASE OF SECURITY INTEREST Recorded Aug 10, 2017
From: MIDCAP FINANCIAL TRUST
To: THE SPECTRANETICS CORPORATION; ANGIOSCORE INC.
Reel/Frame 043518/0142 →
RELEASE OF SECURITY INTEREST Recorded Aug 10, 2017
From: MIDCAP FINANCIAL TRUST
To: THE SPECTRANETICS CORPORATION; ANGIOSCORE INC.
Reel/Frame 043518/0066 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 9, 2016
From: SPECK, ULRICH; BERG, MADELINE C.
To: INNORA GMBH
Reel/Frame 039383/0400 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 9, 2016
From: INNORA GMBH
To: ANGIOSCORE, INC.
Reel/Frame 039383/0425 →
SECURITY INTEREST (TERM) Recorded Dec 11, 2015
From: ANGIOSCORE INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 037273/0804 →
SECURITY INTEREST (REVOLVER) Recorded Dec 11, 2015
From: ANGIOSCORE INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 037273/0822 →
Priority Claims (1)
EP 10160347 · Apr 19, 2010 · regional
Continuity (4)
Continuation 13975209 · Aug 23, 2013
Continuation 13628608 · Sep 27, 2012
Continuation PCTEP2010066754 · Nov 3, 2010
Related Publication 20150297797A1 · Oct 22, 2015